论文部分内容阅读
目的探讨分析阿托伐他汀治疗介入术后冠心病患者的临床疗效与安全性。方法 65例行介入术冠心病患者,随机分为对照组(32例)和观察组(33例)。对照组患者予以常规阿托伐他汀剂量治疗,观察组实施阿托伐他汀大剂量治疗。观察两组患者的治疗效果,进行临床对照性分析。结果两组患者治疗前总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、超敏C反应蛋白(hs-CRP)比较差异均无统计学意义(P>0.05),治疗后观察组患者血脂各项指标以及hs-CRP水平明显优于对照组(P<0.05);观察组患者心脏缺血事件发生率为6.1%,明显低于对照组的25.0%,差异有统计学意义(P<0.05);两组患者不良反应情况比较差异无统计学意义(P>0.05),随着患者身体耐受性提高不良反应逐渐消失。结论阿托伐他汀治疗介入术后冠心病患者的临床疗效好,安全可靠性高,值得在临床实践中推广应用。
Objective To investigate the clinical efficacy and safety of atorvastatin in patients with coronary heart disease after interventional therapy. Methods Sixty-five patients with coronary artery disease were randomly divided into control group (32 cases) and observation group (33 cases). Patients in the control group were treated with conventional atorvastatin, and those in the observation group were given high-dose atorvastatin. To observe the therapeutic effect of two groups of patients, clinical control analysis. Results The levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), hs-CRP (P> 0.05). After treatment, the indexes of serum lipid and the level of hs-CRP in the observation group were significantly better than those in the control group (P <0.05). The incidence of cardiac ischemic events in the observation group was 6.1 %, Which was significantly lower than that of the control group (25.0%) (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05) disappear slowly. Conclusion Atorvastatin treatment of patients with coronary heart disease after PCI has good clinical curative effect, high safety and reliability, and is worth popularizing and applying in clinical practice.